Safety and Immunogenicity of a novel intradermal influenza vaccine in elderly adults (aged >60 years): randomised controlled phase 3 trial results

Background: Each year, seasonal trivalent inactivated influenza vaccines (TIV) provide protection for hundreds of millions of individuals worldwide. Yet there is need to improve vaccine efficacy for the elderly. An influenza vaccine (containing 15µg hemagglutinin/strain), using a novel intradermal (ID) microinjection system, has been developed targeting adults older than 60 years. Methods: A multicentre, randomized controlled phase 3 trial was conducted to assess whether TIV given via ID microinjection induces a superior immune response in adults ≥60 years, compared with an intramuscular (IM) control vaccine (Va…